A Phase 3 Study of HS-20094 in Patients With T2DM
NCT07156539 on ClinicalTrials.gov · last registry update 2025-09-05
Registered but not yet open, with 546 participants planned. Due to report 30 March 2027, alongside 30 other tracked readouts that quarter. Primary outcome, as filed: Change in HbA1c. Sponsors move these dates routinely; any movement since this site started watching is listed below. dulaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- NOT_YET_RECRUITING
- Phase
- P3
- Drug
- dulaglutideTrulicity
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Sponsor type
- Industry
- Enrollment
- 546
- Started
- 2025-09-30
- Primary completion
- 2027-03-30 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in HbA1c
Conditions studied
Type 2 Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.